Nonalcoholic fatty liver disease
Canadian Medical Association Journal2005Vol. 172(7), pp. 899–905
Citations Over TimeTop 1% of 2005 papers
Abstract
Nonalcoholic fatty liver disease is emerging as the most common chronic liver condition in the Western world. It is associated with insulin resistance and frequently occurs with features of the metabolic syndrome. Disease presentation ranges from asymptomatic elevated liver enzyme levels to cirrhosis with complications of liver failure and hepatocellular carcinoma. Current treatment recommendations are limited to weight loss and exercise, although several promising medications are on the horizon. In this article we discuss the etiology, pathogenesis and diagnosis of nonalcoholic fatty liver disease as well as approaches to its management.
Related Papers
- → Fatty Liver Index and Lipid Accumulation Product Can Predict Metabolic Syndrome in Subjects without Fatty Liver Disease(2017)30 cited
- → Prevalence of fatty liver in metabolic syndrome(2020)16 cited
- → Features of myocardial damage indexes in patients with metabolic syndrome and nonalcoholic fatty liver disease(2022)1 cited
- Prevalence survey on fatty liver and metabolic syndrome(2009)
- Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease(2019)